Date: 2014-03-10
Type of information: Collaboration agreement
Compound: DACCAR project
Company: Da Volterra (France) BioAster (France)
Therapeutic area: Infectious diseases
Type agreement:
Action mechanism:
Disease:
Details: * On March 10, 2014, BioAster and Da Volterra announced the signature of a full partnership agreement to develop a new product concept in the field of anti-infection, this follows on from an initial memorandum of understanding signed in 2013. The project, entitled DACCAR, (Destroy Antibiotics in Colon to Combat Antibiotic Resistance), aims to develop an innovative product limiting the emergence of multi-resistant bacteria in patients treated with antibiotics, thus protecting the intestinal microbial flora from antibiotics side effects. Using a DACCAR product could result in minimizing nosocomial infections burden, maintaining the effectiveness of antibiotics (noteworthy carbapenems) reducing the spread of antibiotic resistance.
Financial terms:
Latest news:
